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ABSTRACT 
 
The omega-3 fatty acids in fatty fish and fish oil, eicosapentanoic acid (EPA) and 
docosahexanoic acid (DHA), have been associated with a reduction in risk for 
cardiovascular disease. Blood type is a known contributor to risk for cardiovascular 
events. This study evaluated the effect of fish oil supplements on cardiovascular risk 
markers in adults with blood types A or O. An 8-week parallel-arm, randomized, double-
blind trial was conducted in healthy adult men and women with either blood type A 
(BTA) or blood type O (BTO). Participants were randomized to receive fish oil 
supplements (n=10 [3 BTA/7 BTO]; 2 g [containing 1.2 g EPA+DHA]/d) or a coconut oil 
supplement (n=7 [3 BTA/4 BTO]; 2 g/d). Markers that were examined included total 
cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein 
cholesterol (HDL-C), triglyceride (TG), high-sensitivity C-reactive protein (hsCRP), and 
hemoglobin A1C (HbA1C). Results indicated that the percent change in LDL cholesterol 
was significantly greater in the coconut oil group vs the fish oil group (-14.8±12.2% vs 
+2.8±18.9% respectively, p=0.048).  There were no other significant differences between 
treatment groups, or between blood types A and O, for the other cardiovascular risk 
markers. Further research with a larger and more diverse sample may yield a more 
conclusive result. 
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Chapter 1 
INTRODUCTION 
 In 2010, cardiovascular disease accounted for 31.9% of all deaths in the United 
States (American Heart Association, 2013). For some people with risk for cardiovascular 
disease, taking a dietary supplement may help them to reduce their risk of developing this 
life-threatening ailment. If found to be effective, this treatment method could reduce both 
the financial costs and the health costs for society and many individuals with risk for 
cardiovascular disease risk. 
Much of the traditional medical nutrition therapy for treating cardiovascular 
disease has focused on adjusting intake of fat and sodium. These dietary changes, while 
shown to be highly effective (Aburto et al, 2013; Mozaffarian, Micha, & Wallace, 2010), 
can be difficult for many individuals to make. It has also been well documented that the 
omega-3 fatty acids, eicosapentanoic acid (EPA) and docosahexanoic acid (DHA), in fish 
oil may help to reduce one’s risk for cardiovascular disease by promoting a favorable 
blood lipid profile, stabilizing plaques in arteries, improving blood circulation, and 
reducing inflammation (Anderson & Ma, 2009; Chan & Cho, 2009; Deckelbaum & 
Torrejon, 2012; Dessi, Noce, & Di Daniele, 2013; Gazi, Liberopoulos, Saougos, & Elisaf, 
2006). 
An additional component of this equation is blood type. It has been demonstrated 
that individuals with blood type A seem to have an increased tendency to form blood 
clots, when compared to blood type O. This is thought to be due to higher levels of a 
blood glycoprotein known as von Willebrand factor (de Lorgeril & Salen, 2012). If 
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combined with other risk factors, this may predispose the blood type A individual to 
develop ischemia and infarction; potentially fatal if in the form of a myocardial infarction 
(MI; heart attack) or cerebrovascular accident (CVA; stroke). Because fish oil is known 
to have an antithrombotic effect, it is then feasible that a fish oil supplement regimen may 
reduce blood clotting tendency in individuals with blood type A, thereby reducing the 
risk for a heart attack or stroke. 
An extra area of interest is insulin sensitivity and blood glucose levels. Some 
research suggests that the omega-3 fatty acids in fish oil may increase cellular sensitivity 
to insulin, thereby reducing glucose levels in the blood (American Diabetes Association, 
2010). An abnormally high level of glucose in the blood is damaging to blood vessels and 
prolonged hyperglycemia is a known risk factor for developing or aggravating 
atherosclerosis and cardiovascular disease. 
If taking a dietary supplement such as fish oil is shown to be effective in reducing 
one’s risk of cardiovascular disease, this may be an easy and simple way to improve 
health outcomes for many individuals. 
Purpose of Study 
 The current research study intends to explore the association between fish oil 
supplementation and risk for cardiovascular disease in individuals with blood types A and 
O. Twenty-four healthy participants, eight males and sixteen females, were recruited 
from the greater Phoenix metropolitan area. The participants were stratified by blood type 
and then randomly assigned to one of two treatment groups: fish oil supplementation or 
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coconut oil supplementation. The primary investigators and the participants were blinded 
regarding the supplement type. 
Research Aim and Hypotheses 
 In the current study, the fish oil supplement condition involved taking a gel 
capsule containing 1000 mg of fish oil, with 400 mg EPA and 200 mg DHA, twice a day 
for eight weeks. The coconut oil supplement condition involved taking a gel capsule 
containing 1000 mg of coconut oil twice a day for eight weeks. The researchers predicted 
that an increase in omega-3 fatty acid intake would result in improved blood lipids and 
reduced inflammation. However, the primary hypothesis of the current study is that the 
fish oil supplementation will not change lipid profiles and inflammatory markers in 
healthy adults in Phoenix, Arizona. A secondary hypothesis is that fish oil 
supplementation will not change glucose control in healthy adults in Phoenix, Arizona. 
The researchers predicted that supplementation with coconut oil would not change the 
blood lipid profile, inflammation, or glucose control. 
Definition of Terms 
EPA: Eicosapentanoic acid is a very long-chain polyunsaturated fatty acid with 20 carbon 
molecules 5 double bonds along the length of its chain. It is an omega-3 fatty acid 
due to the presence of a double-bond at the third carbon from the methyl terminus. 
It is a component of tissues in the body. 
DHA: Docosahexanoic acid is a very long-chain polyunsaturated fatty acid with 22 
carbon molecules 6 double bonds along the length of its chain. It is an omega-3 
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fatty acid due to the presence of a double-bond at the third carbon from the methyl 
terminus. It is major component of the central nervous system and the retina. It is 
needed optimal brain and eye development and maintenance. 
hsCRP: high-sensitivity C-reactive protein biomarker that assesses the presence of 
inflammation. Less than 1.0 mg/L = Low Risk for CVD; 1.0 – 2.9 mg/L = 
Intermediate Risk for CVD; greater than 3.0 mg/L = High Risk for CVD. 
Inflammatory disease: A condition in which there is an inflammatory response within the 
body; examples include: infection, rheumatoid arthritis, cardiovascular disease, 
atherosclerosis, celiac disease, inflammatory bowel disease, inflammatory bowel 
syndrome, asthma, and more. 
Delimitations and Limitations 
Participants are healthy male and female adults between the ages of 18 and 50 
years. They were recruited in Phoenix, Arizona. They were not taking fish oil 
supplements when recruited into the study. There was no exclusion for the use of other 
supplements.  
A limitation of this study is that the sample size was relatively small and 
minimally diverse. Therefore, further study will be needed for enhanced generalizability. 
Also, the dose and period of time of the supplementation may not have been enough to 
produce a statistically significant result. Finally, blood samples were not specifically 
designed to be taken from a fasting state. Whether or not individuals had been fasting at 
the time of the blood draw is unknown. Therefore, it is uncertain whether serum 
5 
 
triglyceride measurements, as well as LDL cholesterol (LDL-C) measurements, were 
influenced by recent lipid intake. 
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Chapter 2 
REVIEW OF LITERATURE 
Cardiovascular Disease 
 Cardiovascular disease (CVD) is defined as disease of the heart and vasculature 
system (Alpert, 2004). It is the leading cause of death in the United States, as well as in 
many other countries around the world, for both males and females (Alpert, 2004; de 
Lorgeril & Salen, 2012). The majority (50-60%) of deaths from CVD are a result of 
sustained ventricular arrhythmias or sudden cardiac death, meaning death within one hour 
of a myocardial infarction (MI; heart attack) (Gazi et al, 2006). It is also the most 
common cause of death for individuals with type 1 (T1DM) and type 2 diabetes mellitus 
(T2DM). Some risk factors for this disease are physical inactivity, poor diet, obesity or 
overweight, hypertension, aging, genetic factors, smoking, and stress (Alpert, 2004). 
Blood Lipid Profile 
The blood lipid profile is commonly measured to assess one’s likelihood of 
developing CVD. The major components that make up the human blood lipid profile 
include: low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein 
cholesterol (HDL-C), intermediate-density lipoprotein cholesterol (IDL-C), very-low-
density lipoprotein (VLDL-C), and triglycerides (TG). A lipoprotein is a particle in the 
general blood circulation that is used to transport lipids; cholesterol and triglycerides in 
particular. The structure of a lipoprotein consists of an outer monolayer of polar 
phospholipids and free cholesterol. It has a core of nonpolar triglycerides and cholesterol 
esters. On its surface are integral and peripheral apoproteins that act as identifying and 
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signaling molecules. The concept of higher or lower density refers to the proportion of 
lipid to protein, with more protein and less lipid contributing to a higher density (Judge, 
Phalen, & O’Shea, 2010). 
Very-low density lipoprotein (VLDL) is released into the bloodstream by the 
liver. While in the blood, VLDL matures into intermediate-density lipoprotein (IDL), and 
then to low-density lipoprotein (LDL). LDL is responsible for transporting cholesterol 
from the liver to cells. Here, the cholesterol is incorporated into the cell membrane or 
stored as cholesterol esters. High-density lipoprotein (HDL) is produced by enterocytes 
and released into the bloodstream. It is responsible for removing any excess cholesterol 
from cells and bringing it back to the liver (Klop & Cabezas, 2013; Sharma, Farmer, & 
Garber, 2011; Tonkin & Byrnes, 2014).  
According to the Adult Treatment Panel (ATP)-III guidelines from the National 
Cholesterol Education Program (NCEP), LDL-cholesterol (LDL-C) should be <100 
mg/dL, HDL-cholesterol (HDL-C) should be >60mg/dL, and VLDL-cholesterol  
(VLDL-C) should be 0-29 mg/dL (National Institutes of Health, 2001). The total 
cholesterol (TC) level in the blood is a sum of the cholesterol within these three 
lipoproteins. ATP-III guidelines state that total cholesterol (TC) should be <200 mg/dL. 
The laboratory test for serum triglycerides (TG) is a measure of the total amount of 
triglycerides present in the LDL, HDL, IDL, and VLDL. A normal serum triglyceride 
level is considered <150 mg/dL. It is important to recognize that the measurement for 
serum TGs also detects any TGs absorbed into the bloodstream from recent food intake. 
Therefore, the measure is most meaningful when the blood sample is from a fasting state. 
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An aberration from any of the aforementioned values is known as dyslipidemia which 
indicates an increased risk for developing cardiovascular disease (CVD) (Chan & Cho, 
2009; Rudkowska, 2012). 
An abnormally high level of triglycerides, or hypertriglyceridemia, is an 
independent risk factor for developing coronary heart disease (CHD) and ischemic 
cerebrovascular accident (CVA; stoke) (American Heart Association, 2013). This is 
largely due to the fact that the highly-atherogenic lipoproteins, VLDL and IDL, are the 
primary carriers of triglycerides. Thus, a higher triglyceride level is associated with 
higher levels of these lipoproteins and therefore a higher risk for atherosclerosis. Another 
mechanism by which high triglycerides are thought promote CHD is through the 
competition of triglyceride-rich lipoproteins with HDL, resulting in a decreased 
production of HDL. This also contributes to an increased density and decreased size of 
LDL particles, making them more atherogenic (Chan & Cho, 2009; Klop & Cabezas, 
2013). 
Inflammation 
Another indication of CVD risk is inflammation. Inflammation is a process that 
occurs within the body in response to stress, to the presence of foreign agents such as 
bacteria, and to trauma. In the case of infection or trauma, inflammation is necessary to 
assist with destruction of bacteria and promotion of healing. It can be maladaptive, 
however, in the case of stress. The everyday stresses of modern life can be a major 
contributor to increased levels of inflammation. The chemical mediators that are released 
in the process of an inflammatory response can be damaging to body tissues via 
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oxidation. With stress however, there is no real physiologic benefit from the 
inflammation to justify this damage. Inflammation from stress also tends to be chronic 
rather than passing, which can increase risk for such disease processes as hypertension, 
atherosclerosis, and CVD (Calder, 2013; Dessi, Noce, & Di Daniele, 2013).  
The existence and degree of inflammation is commonly assessed using high-
sensitivity C-reactive protein (hsCRP) which increases in the presence of inflammation. 
Normal hs-CRP is any value less than 1 mg/L. The higher the value, the more 
inflammation is present and the higher the risk for cardiovascular disease (CVD). 
Unfortunately, this can also indicate acute inflammation as occurs in infection or allergic 
reactions. Thus, it is not specific enough by itself to necessarily signify the chronic 
inflammation that relates to chronic diseases such as CVD. There is a laboratory test that 
is more specific to chronic inflammation called erythrocyte sedimentation rate (ESR), or 
sed rate, that is very simple and relatively inexpensive to conduct. A normal ESR for 
males younger than 50 years old is less than 15 mm/hr. For males 50 years old and older, 
less than 20 mm/hr is considered normal. For females younger than 50 years old a normal 
value is less than 20 mm/hr, while less than 30 mm/hr is considered normal for females 
50 years old and older (National Institutes of Health, 2012).  
Atherosclerosis 
The progression of CVD often begins with the accumulation of lipids in the 
vasculature system which then becomes calcified into plaques; a disease process known 
as atherosclerosis. Atherosclerosis is defined as hardening of the arteries. It is triggered 
by and exacerbated by a combination of inflammation and elevated levels of cholesterol 
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in the blood (hypercholesterolemia). Risk factors for developing atherosclerosis include: 
hypercholesterolemia, hypertriglyceridemia, hypertension, low HDL-C, smoking, and 
diabetes mellitus (Calder, 2013; Dessi, Noce, & Di Daniele, 2013). 
The process of atherosclerosis begins when, for any reason, the endothelial layer 
of an artery sustains injury. Chemicals called chemo-attractants are subsequently released 
at the site following the injury. The immune cells, monocytes and leukocytes, migrate to 
and adhere to the site of injury in response. This process is known as chemotaxis (Calder, 
2013). The expression of intracellular cell adhesion molecule 1 (ICAM-1) and vascular 
cell adhesion molecule 1 (VCAM-1) then increases; enhancing the adhesion of 
monocytes to the endothelial cells. This spurs an inflammatory process in which 
cytokines are released, attracting the phagocytic cells known as macrophages to the area. 
These macrophages then engulf circulating particles of LDL and, becoming engorged 
with lipids, are converted to foam cells (Dessi, Noce, & Di Daniele, 2013). High levels of 
cholesterol in the blood encourage this step of the process, especially when LDL becomes 
oxidized due to inflammation. The foam cells infiltrate the damaged endothelium of the 
artery, forming a fatty streak. Then, smooth muscle cells migrate into the intima layer of 
the artery and proliferate, forming what is known as a fibrous cap and completing the 
formation of an arterial plaque (Dessi, Noce, & Di Daniele, 2013).  
The more lipid that accumulates in the arteries, the more that they become 
occluded and the greater the chances are for blockage and ischemia. This is known as 
arterial stenosis, or thickening of the arteries. The plaques that form are not typically 
dangerous as long as they are stable. With continuous disturbance via inflammation or 
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blood pressure changes however, these plaques have the potential to burst. When this 
happens, the materials that are released can cut off blood supply to muscles and organs. 
Depending on where the blockage occurs, this can result in thrombosis, skeletal muscle 
infarction, cerebrovascular accident (CVA; stroke), or myocardial infarction (MI; heart 
attack). The last two have the potential to become fatal very quickly (Alpert, 2004; 
Calder, 2013; Dessi, Noce, & Di Daniele, 2013). The goal of nutrition therapy for 
atherosclerosis is to shrink the size of these plaques and maintain their stability. 
Atherosclerotic cardiovascular disease includes coronary heart disease (CHD), 
peripheral artery disease (PAD), and stroke (cerebrovascular accident; CVA). This 
disease class represents the number one cause of death around the world. Abnormal 
levels of blood lipids (dyslipidemia), along with smoking and hypertension, account for 
as many as 75% of all cases of atherosclerotic cardiovascular disease (Tonkin & Byrnes, 
2014).  
Dietary Fat 
 One of the macronutrients that makes up the natural human diet is dietary fat, also 
known as lipids. Consuming fat from the diet is necessary for the purpose of providing 
essential fatty acids. It is also needed to sustain lipid storage within adipose tissue. 
Adipose tissue is beneficial for its contribution to body temperature control, organ 
protection, and providing for energy needs in certain situations. During carbohydrate 
deprivation or starvation, fat can be burned for energy in order to spare the protein in 
muscle. The Acceptable Macronutrient Distribution Range (AMDR) for dietary fat is 25-
35% of total kilocalories for healthy individuals. It is important to recognize that it is the 
12 
 
type and quality of the fat consumed that matters, more so than the quantity (Scholl, 
2012). 
The fat in the food we consume exists in the form of triglycerides. When a  
fat-containing meal is consumed, the fat is emulsified by bile from the liver to enhance its 
digestibility (Klop & Cabezas, 2013). Then, these triglycerides are lipolyzed, or broken 
down, by lipase enzymes from the pancreas into free fatty acids (FFA) and  
2-monoacylglycerols (2-MAG). The enterocytes that line the small intestine take up these 
components via passive diffusion and transporters such as CD36. Within the enterocyte, 
the FFAs and 2-MAGs are reassembled into triglycerides (Klop & Cabezas, 2013). At 
this point, any cholesterol that is consumed is also taken up by the enterocyte and 
converted into cholesterol esters. Then, the triglycerides and cholesterol esters are 
packaged into chylomicrons with phospholipids and apolipoprotein B48 (apoB48). The 
chylomicrons are released from the enterocyte into the lymph system where they are 
transported to blood circulation through the thoracic duct. They then are taken up by the 
liver where they are used to manufacture very low density lipoprotein (VLDL). VLDL 
has a similar structure to chylomicrons, though apolipoprotein B100 (apoB100) is 
involved rather than apoB48. VLDL is then released into the bloodstream by the liver 
where it is converted to IDL and then to LDL (Klop & Cabezas, 2013).  
As mentioned previously, triglycerides have three fatty acids attached to a 
glycerol backbone. The two major classifications for fatty acids are saturated fatty acids 
and unsaturated fatty acids. A saturated fatty acid only has single carbon-to-carbon bonds 
and no double-bonds. They are solid at room temperature. With regards to blood lipid 
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levels, saturated fatty acids have been shown to elevate levels of cholesterol in LDL and 
HDL. Common dietary sources of saturated fatty acids are flesh from animals, 
fat-containing dairy products, and tropical oils. The recommended level of intake for 
saturated fat is less than 10% of total kilocalories (Skerrett & Willett, 2010). 
An unsaturated fatty acid possesses one or more carbon-to-carbon double bonds. 
They are liquid at room temperature. Generally, these are reported to decrease blood 
levels of LDL-C (Mozaffarian, Micha, & Wallace, 2010). Within the category of 
unsaturated fatty acids are monounsaturated fatty acids and polyunsaturated fatty acids. A 
monounsaturated fatty acid has one carbon-to-carbon double bond at some point along its 
chain. A polyunsaturated fatty acid is one which possesses two or more carbon-to-carbon 
double bonds along the length of its chain (Anderson & Ma, 2009; Skerrett & Willett, 
2010). 
An additional category is trans fatty acids. These originate as unsaturated fatty 
acids but are chemically altered to mimic saturated fatty acids with a process called 
hydrogenation. Thus, they are solid at room temperature. This is intended to increase 
stability. These have been shown to not only increase blood levels of LDL-C, but also to 
decrease HDL-C levels in the blood (Michas, Micha, & Zampelas, 2014). Typically, they 
do not naturally occur in food and are often added to food during processing to prolong 
shelf-life. Trans fats are to be completely avoided in the diet for optimal heath (Michas, 
Micha, & Zampelas, 2014; Skerrett & Willett, 2010). 
Polyunsaturated fatty acids can be further classified as omega-3 or omega-6, 
depending on the position of the first carbon-to-carbon double bond with respect to the 
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methyl terminus. Linoleic acid (LA) is the parent fatty acid of the omega-6 subgroup and 
alpha-linolenic acid (ALA) is the parent fatty acid of the omega-3 subgroup. Both are 
essential, meaning that they cannot be produced by the human body and must be obtained 
from the diet (Anderson & Ma, 2009). LA is found in vegetable oils, seeds and nuts and 
ALA is found in leafy vegetables, walnuts, soybeans, flaxseed, and seed and vegetable 
oils. LA and ALA can be further converted via elongation and desaturation into  
long-chain polyunsaturated fatty acids which are physiologically active within the body 
(Deckelbaum & Torrejon, 2012).  LA is metabolized to arachidonic acid (AA), while 
ALA can be metabolized to eicosapentanoic acid (EPA) and then to docosahexanoic acid 
(DHA). Unfortunately, these conversions from LA and ALA do not happen to a 
significant extent within the body and these fatty acids are often used for energy instead. 
Thus, obtaining the longer-chain derivatives directly from food is typically a much more 
efficient way of maintaining adequate levels within the body (Deckelbaum & Torrejon, 
2012). AA can be obtained from consuming animal fat and dairy fat. EPA and DHA can 
be obtained from consuming marine products such as fish, mussels, oysters, and seaweed 
(Anderson & Ma, 2009). A proper balance of omega-3 fatty acids to omega-6 fatty acids 
is important for optimal health. A ratio between 1:1 and 4:1 has been shown to be 
beneficial. Furthermore, a ratio of polyunsaturated fatty acids to saturated fatty acids 
between 1.5:0 and 2:0, or greater, is ideal (Houston, 2014). 
 
 
15 
 
Table 1. Adequate Intake (AI) for LA and ALA (Houston, 2014) 
Age/Lifestage LA AI (g/day) ALA AI (g/day) 
0-6 months 4.4 0.5 
7-12 months 4.6 0.5 
1-3 years 7 0.7 
4-8 years 10 0.9 
9-13 years Male: 12, Female: 10 Male: 1.2, Female: 1 
14-18 years Male: 16, Female: 11 Male: 1.6, Female: 1.1 
19-50 years Male: 17, Female: 12 Male: 1.6, Female: 1.1 
>50 years Male: 14, Female: 11 Male: 1.6, Female: 1.1 
Pregnancy 13 1.4 
Lactation 13 1.3 
 
There is not currently an established AI for EPA or DHA. It is important to note 
that these AI’s are based only on preventing deficiency, not optimal intake. Also, they do 
not provide a recommended ratio of omega-3 to omega-6 fatty acids (4:1, 6:3, or 1:1; 4:1 
is optimal) (Houston, 2014). 
Omega-3 Fatty Acids 
The structural characteristic that makes a polyunsaturated fatty acid an omega-3 
fatty acid, is the double bond between carbon molecules at the third position from the 
methyl terminus of the fatty acid chain. The majority of research involving omega-3 fatty 
acids has focused on three subtypes in particular: alpha-linolenic acid (ALA), 
eicosapentanoic acid (EPA), and docosahexanoic acid (DHA) (Chan & Cho, 2009).  
Humans do not possess the necessary metabolic pathways to intrinsically generate 
the essential fatty acid known as ALA. ALA can, however, be obtained from the diet and 
be subsequently converted to EPA and DHA. Even so, this pathway occurs at such a low 
rate (about 5% to EPA and less than 0.5% to DHA) that it is more effective to obtain 
EPA and DHA directly from food (Chan & Cho, 2009; Dessi, Noce, & Di Daniele, 
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2013). EPA and DHA are highly prevalent in fatty fish, which store fat as triglycerides in 
their flesh rather than in their livers like non-fatty fish (Gazi et al, 2006). Fatty fish 
typically inhabit cold water (Deckelbaum & Torrejon, 2012). They include but are not 
limited to: salmon, mackerel, sardines, anchovies, herring, trout, halibut, and tuna. 
Although they are not technically considered fish, oysters and mussels are also included 
in this category (Albert, Cameron-Smith, Hofman, & Cutfield, 2013). 
EPA is a component of tissues in the body and it may be protective against heart 
disease by reducing inflammation. DHA is a major component of the central nervous 
system and the retina. It is therefore necessary for optimal brain and eye development and 
maintenance (Albert et al, 2013). Adequate intake has been linked to a decreased risk for 
depression and suicide attempt, as well as with potentially reducing the speed and 
severity of cognitive decline in older age (Albert et al, 2013; Deckelbaum & Torrejon, 
2012). 
Research suggests that ALA does not convey the same benefits as its longer-chain 
metabolites, EPA and DHA. Furthermore, the conversion of ALA to EPA and DHA is 
not efficient enough to prevent deficiency. Therefore, it appears that it is necessary to 
consume EPA and DHA directly in order to fully obtain their respective health benefits 
(Anderson & Ma, 2009; Dessi, Noce, & Di Daniele, 2013). 
Fish Oil Supplements 
Aside from consuming whole fish, a common and readily available source of the 
omega-3 fatty acids EPA and DHA is fish oil in the form of a gel capsule supplement. It 
has been estimated that over one-third of American adults use some form of marine 
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omega-3 fatty acid supplement (Albert et al, 2013). Though obtaining these fatty acids 
through eating fatty fish is ideal, it is often not possible to eat the recommended amount 
on a consistent basis due to factors such as taste preference, location, and cost. A dose of 
500 mg/day of EPA plus DHA is equivalent to approximately 2 servings of fish per week. 
This also fulfills the recommendation regarding fatty fish intake for healthy people from 
the American Heart Association (AHA). For individuals with coronary artery disease 
(CAD), the AHA recommends 1000 mg/day of EPA plus DHA. This is equivalent to 
approximately 4 servings of fish per week. (Chan & Cho, 2009).  
The standard concentration of EPA and DHA in a fish oil supplement is about 
30%, meaning that a 1000 mg capsule contains a combined total of 300 mg EPA and 
DHA (Calder, 2013). An EPA to DHA ratio of 3-4 to 2 in fish oil supplements has been 
shown to be most beneficial (Houston, 2014). For those with serum triglyceride levels 
greater than 500 mg/dL, the AHA recommends taking an omega-3 acid ethyl esters 
medication (i.e. Lovaza). This contains 465 mg of EPA and 375 mg of DHA in a 1000 
mg capsule and the recommended dosage is two to four times per day. This high 
concentration (84% EPA and DHA) is not currently available over the counter and must 
be obtained with a prescription. Effective doses in research are typically between 3000 
and 5000 mg per day (Gazi et al, 2006). 
Fish oil supplements have been widely recognized for their benefits in 
cardiovascular health. They have been shown to lower serum triglyceride levels, as well 
as reduce blood pressure and inflammation. Interestingly, this reduction in inflammation 
is sometimes but not always represented by a reduced high-sensitivity C-reactive protein 
18 
 
(hs-CRP) level (Chan & Cho, 2009; Dessi, Noce, & Di Daniele, 2013; Swanson, Block, 
& Mousa, 2012). Rather, the reduction in inflammatory processes is represented by 
inhibited leukocyte chemotaxis, decreased expression of adhesion molecules, decreased 
eicosanoid and cytokine production, and reduced T cell reactivity (Anderson & Ma, 
2009; Calder, 2013; Chan & Cho, 2009, Gazi et al, 2006). Additionally, some studies 
suggest a benefit in reducing cardiac arrhythmias from fish oil supplementation (Chan & 
Cho, 2009; Gazi et al, 2006). 
As with all dietary supplements, the use of fish oil can potentially have some 
negative side effects, particularly when taken in excess. Some individuals may 
experience gastrointestinal distress. Another common complaint is the fishy-odor that can 
arise with belching. Many capsules today have an enteric coating that prevents this minor 
side effect. Another potential side effect is worsened glycemic control in those with 
diabetes (Gazi et al, 2006; Chan & Cho, 2009).  Also, fish oil is known to be an 
anticoagulant through its action to inhibit the arachidonic acid pathway. As a result, those 
who are planning to have surgery are often asked to discontinue taking fish oil for a 
month before the surgery to reduce risk of uncontrollable bleeding (Gazi et al, 2006; 
Chan & Cho, 2009).  
 
 
 
 
19 
 
Table 2. Side Effects Associated with Fish Oil Supplementation (Gazi et al, 2006) 
 Fish Oil Supplement Daily Dose 
Side Effect <1000 mg/day 1000-3000 mg/day >3000 mg/day 
Fishy aftertaste Low risk Moderate risk Likely 
Gastrointestinal upset Very low risk Moderate risk Moderate risk 
Clinical bleeding Very low risk Very low risk Low risk 
Poorer glycemic control* Very low risk Low risk Moderate risk 
Elevated LDL-C† Very low risk Moderate risk Likely 
 
*In individuals with impaired glucose tolerance (IGT) or diabetes mellitus (DM) 
†In individuals with hypertriglyceridemia 
 
It is important to consider the potential for fish oil supplements, as well as whole 
fish, to contain methylmercury (MeHg) which is a potentially harmful contaminant. 
MeHg is considered a neurotoxin, meaning that it is damaging to cells in the nervous 
system. When exposure occurs during the developmental stage of life, particularly the 
prenatal period, defects in cognitive development and function have been documented. In 
adults, sensory disorders and tremors have been reported with MeHg exposure 
(Ceccatelli, Daré, & Moors, 2010). Choosing a purified supplement and lower-mercury 
fish may be helpful in reducing risk for consumption of this substance (Gazi et al, 2006). 
Examples of lower-mercury fish that are also good sources of EPA and DHA include: 
salmon, mackerel (non-King variety), sardines, anchovies, herring, and trout (Mahaffey, 
2008). 
 Unfortunately, the world’s existing population of cold water fatty fish may not be 
enough to sustain Europeans and North Americans with the recommended levels of EPA 
and DHA intake (Deckelbaum & Torrejon, 2012; Raatz, Silverstein, Jahns, & Picklo, 
2013). Interestingly, like humans, fatty fish are also unable to generate omega-3 fatty 
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acids on their own. Their stores actually originate from the single cell marine organisms 
and marine plants that they consume, such as algae, krill, and seaweed (Deckelbaum & 
Torrejon, 2012; Gazi et al, 2006; Lenihan-Geels, Bishop, & Ferguson, 2013; Raatz, 
Silverstein, Jahns, & Picklo, 2013). Looking to these alternative and more sustainable 
sources may be necessary to maintain future needs. At the current time, these sources are 
significantly more expensive to cultivate than fish. Developing more efficient cultivation 
methods will be critical to ensuring long-term feasibility and sustainability (Deckelbaum 
& Torrejon, 2012; Lenihan-Geels, Bishop, & Ferguson, 2013). 
 The supplemental form of coconut oil has been used in past research studies as a 
placebo for fish oil. Its use has been justified by the fact that it does not contain 
polyunsaturated fatty acids and it does not alter the metabolism of omega-3 
polyunsaturated fatty acids (Amminger et al, 2013; Karr, Grindstaff, & Alexander, 2012; 
Mozaffari-Khosravi, Yassini-Ardakani, Karamati, & Shariati-Bafghi, 2013; Trepanowski, 
Kabir, Alleman, & Bloomer, 2012). 
Fish Oil Supplementation and Cardiovascular Disease 
Cultures with relatively high fish intake, such as the Inuit populations of northern 
Canada and Alaska, have lower incidence and prevalence than what would be expected 
when considering their high overall fat intake. Similarly, the Japanese traditionally 
consume a diet rich in seafood, as well as in sodium. Nevertheless, the prevalence of 
CVD in Japan is low when compared with many other countries. The common factor in 
these two cultures is a high intake of seafood (up to 5000-15,000 mg of EPA and DHA 
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per day), suggesting that this may be protective against CVD development (Gazi et al, 
2006). 
Fish Oil Supplementation and Blood Lipids 
With regards to medical nutrition therapy, common recommendations for 
preventing and treating cardiovascular disease have been a reduced intake of omega-6 
fatty acids and saturated fatty acids, while increasing intake of polyunsaturated fatty 
acids. Omega-3 polyunsaturated fatty acids have been thoroughly examined in particular 
(de Lorgeril & Salen, 2012). 
Epidemiological research has shown that Greenland Eskimos, who are known to 
consume a relatively high amount of omega-3 fatty acids through fish, have lower 
incidence of cardiovascular disease (Bjerregaard & Johansen, 1987). Since this discovery 
about three and a half decades ago, the potential cardiovascular health benefits of fish oil 
have been widely studied and documented (Chan & Cho, 2009). 
One mechanism by which EPA and DHA work to lower triglyceride levels has 
been seen in both animal and human studies. This involves decreasing VLDL synthesis in 
the liver and increasing its release into the bloodstream (Chan & Cho, 2009; Gazi et al, 
2006; Weitz, Weintraub, Fisher, & Schwartzbard, 2010). It has been found that the 
conversion to IDL and then to LDL occurs more quickly with increased intake of EPA 
and DHA, explaining the increase in LDL-C that often occurs with fish oil 
supplementation (Gazi et al, 2006). Another theory is that EPA and DHA increase the 
activity of lipoprotein lipase which results in increased chylomicron clearance from the 
bloodstream. Studies have shown that the higher the dose and the higher the baseline 
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serum triglyceride level, the greater the effect that fish oil appears to have (Chan & Cho, 
2009; Dessi, Noce, & Di Daniele, 2013; Judge, Phalen, & O’Shea, 2010; Weitz, 
Weintraub, Fisher, & Schwartzbard, 2010). This is particularly true with prescription- 
concentration fish oil (i.e. Lovaza) for very high triglyceride levels (Chan & Cho, 2009). 
A third mechanism by which EPA and DHA are thought to lower triglyceride levels in 
the blood is by decreasing triglyceride synthesis, possibly through inhibition of the sterol 
regulatory element-binding protein (SREBP) pathway. Finally, EPA and DHA appear to 
increase triglyceride clearance from the blood by the liver (Anderson & Ma, 2009). 
A study by Pownall et al. found that in participants with hypertriglyceridemia, 
those receiving the therapeutic dose of 4000 mg fish oil per day experienced a 38.9% 
decrease serum triglyceride levels. Those receiving the placebo had a 7.8% decrease. 
There was no significant effect on HDL-C, but there was a 16.7% increase in LDL-C 
with fish oil (1999). 
A meta-analysis found that with every 1000 mg increase in fish oil dosing, serum 
triglyceride decreases by about 8 mg/dL. Of those with high baseline triglyceride levels 
the reduction was even more dramatic, with an average serum triglyceride decrease of 27 
mg/dL, an average HDL-C increase of 1.6 mg/dL, and an average LDL-C increase of 6 
mg/dL. There was no significant change in total cholesterol levels (Balk et al, 2006). 
An analysis of 36 crossover studies found that a fish oil dosing of 3000 to 4000 
mg per day decreased serum triglyceride levels by 24% in participants with 
normolipidemia and 35% in participants with hypertriglyceridemia. A 5-10% increase in 
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LDL-C and a 1-3% increase in HDL-C was also seen. The association between fish oil 
and triglycerides appeared to be dose-dependent (Harris, 1997). 
A clinical trial examined the use of highly concentrated omega-3 acid ethyl esters 
in 42 participants who had severe hypertriglyceridemia with serum levels between 500 
and 2000 mg/dL. With the dose at 4000 mg per day, there was a 45% decrease in 
triglycerides, a 15% decrease in total cholesterol, a 32% decrease in VLDL-C, a 13% 
increase in HDL-C, and a 31% increase in LDL-C (Harris et al, 1997). 
Another trial was made up of 30 participants with triglyceride levels between 354 
and 2478 mg/dL. A daily dose of 4000 mg/dL of omega-3 fatty acids produced a similar 
effect on blood lipids and lipoproteins as a 1200 mg daily dose of gemfibrozil. 
Interestingly, although LDL-C was increased by both therapies, the LDL particles 
became larger, more buoyant, and thus less atherogenic as a result (Dessi, Noce, & Di 
Daniele, 2013; Gazi et al, 2006). 
A review of 21 trials found that fish oil consumption resulted in a net change of    
-21 mg/dL for triglycerides, +1.6 mg/dL for HDL-C, and +6 mg/dL for LDL-C. Larger 
doses of fish oil were associated with greater effects on serum triglyceride levels. No net 
effect on total cholesterol was found (Gazi et al, 2006). 
Pharmacological Therapy vs. Fish Oil Supplementation for Hyperlipidemia 
A commonly utilized pharmaceutical therapy for hyperlipidemia is a medication 
class known as a statin. Also known as HMG-CoA-reductase inhibitors, these drugs are 
fairly efficacious in reducing LDL-C, but only have a moderate effect on reducing 
triglycerides (Chan & Cho, 2009). Fish oil has been demonstrated to lower serum 
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triglyceride levels and increase LDL-C levels. It is important to note, however, that the 
amount LDL-C increases is only about 6-10 mg/dL and the size and buoyancy of the 
LDL particles is also increased, making them less likely to be atherogenic (Chan & Cho, 
2009). A randomized, placebo-controlled study demonstrated that in obese men, a 
combination therapy of 40 mg of atorvastatin and 4000 mg fish oil resulted in a 40% 
decrease in serum triglycerides (P=0.002). This is compared to atorvastatin alone which 
had a 26% decrease and fish oil alone which had a 25% decrease. LDL-C levels 
decreased to a similar degree in both the combination therapy group and the atorvastatin 
group (Chan, Watts, Nguyen, & Barrett, 2002). The use of fish oil along with a statin 
may be a more effective therapy for those with both high LDL-C and high serum 
triglyceride levels than simply a statin alone (Athyros, Tziomalos, & Mikhalidis, 2011; 
Chan & Cho, 2009). 
Another important issue to consider is that the use of statins is associated with 
adverse side effects in some individuals. The risk for side effects appears to be  
dose-dependent, though this may vary across individuals due to differences in genetic 
components and disease states. Drug or drug-nutrient interactions may also increase the 
potency, and thus the risk of side effects, for statins. Foods that can potentially interact 
with statins are grapefruit, pomegranate, and the Seville orange. One potential side effect 
of statins that is especially feared is rhabdomyolysis, a severe form of muscle damage 
that results in elevated creatinine kinase (CK) and can lead to renal failure and even 
death. Other adverse side effects that have been reported include: cognitive loss, myositis 
(muscle inflammation), myalgia (muscle pain), nerve damage (neuropathy), pancreatic 
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dysfunction, hepatic dysfunction, and sexual dysfunction (Golomb & Evans, 2008). If, 
because of fear for these side effects, an individual decides to discontinue or never 
initiate use of statins, having an alternative option may be very important to managing 
their lipid levels and potentially avoiding life-threatening consequences.  
Fish Oil Supplementation and Inflammation 
The omega-6 fatty acid arachidonic acid (AA) is essential and contributes to 
cellular function when it is metabolized into prostaglandins, leukotrienes, and 
thromboxanes, a group that is collectively called eicosanoids (Anderson & Ma, 2009; 
Chan & Cho, 2009). Some of these metabolites have pro-inflammatory characteristics, 
while others can contribute to arrhythmia. It is important to note that EPA is competitive 
with AA for the same enzymatic pathway. It can also be converted to these eicosanoids. 
However, the products from EPA’s conversion are far less inflammatory than those 
produced by conversion of AA. Certain products from DHA, specifically resolvins and 
protectins, are even considered to be anti-inflammatory (Buckley & Howe, 2010; Dessi, 
Noce, & Di Daniele, 2013; Calder, 2013). As a result of competition with AA, EPA 
results in decreased production of AA-derived eicosanoids. This then reduces platelet 
aggregation, vasoconstriction, and leukocyte chemotaxis and adherence. Ultimately, this 
reduces the potential risk for plaque formation, thrombus formation, and ischemic events 
(Anderson & Ma, 2009, Chan & Cho, 2009, Gazi et al, 2006).  
Beyond EPA’s competition with AA, fish oil is associated with a reduction in 
inflammation through its inhibition of pro-inflammatory factors. EPA can inhibit 
interleukin-2 (IL-2) production and both EPA and DHA can inhibit interleukin-1B (IL-
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1B), tumor necrosis factor alpha (TNFα), interleukin-6, and interleukin-8 production 
(Anderson & Ma, 2009). 
Although fish oil has long been heavily touted anti-inflammatory properties, there 
has been limited biochemical evidence to demonstrate this effect in previous studies. A 
meta-analysis by Balk et al. (2006) examined four studies and found a minimal net 
change in hs-CRP that ranged from –0.15 to +1.7 mg/L with fish oil doses between 1600 
g/day and 5900 g/day. Perhaps looking at sed rate rather than hs-CRP would provide a 
clearer picture of how fish oil may influence inflammation. 
With regards to atherosclerosis, a major mechanism by which EPA and DHA are 
thought to function has to do with the inflammatory processes that promote and aggravate 
atherogenesis. A study by Dwyer et al. (2004) showed that high omega-3 fatty acid intake 
reduces the function of leukotriene-mediated inflammatory pathways. Also, EPA and 
DHA have been found to inhibit the expression of intracellular cell adhesion molecule 1 
(ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) on endothelial cells and 
monocytes. This impedes the atherosclerotic pathway, thereby reducing the risk for 
myocardial infarction and stroke. Additionally, it has been demonstrated that EPA and 
DHA reduce the generation of the chemoattractants involved in atherogenesis. These 
include: leukotriene B4, platelet-activating factor (PAF), monocyte chemoattractant 
protein-1 (MCP-1), platelet-derived growth factor (PDGF), interleukins, and tumor 
necrosis factor-a (TNFa). (Gazi et al, 2006). 
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Fish Oil Supplementation and Atherosclerosis 
As has been discussed, fish oil supplementation has been shown to reduce the risk 
for developing atherosclerosis through its impact on blood lipids and inflammation. There 
is also evidence to suggest that EPA and DHA from fish oil improve the state of 
preexisting atherosclerosis. Although fish oil supplementation does not prevent 
recurrence of stenosis after angioplasty, it may help to stabilize existing arterial plaques. 
One study found that participants who received 1400 mg of fish oil supplementation 
before carotid endarterectomy had higher levels of EPA and DHA in their carotid plaques 
when compared with the control group. This was associated with thicker fibrous caps of 
the plaques, decreased inflammatory markers, and lower number of arterial wall 
macrophages. This translates to a reduced risk for atherosclerosis-related complications 
(Thies et al, 2003).  
Fish Oil Supplementation and Cardiovascular Function 
There is some evidence to suggest that fish oil may reduce cardiac arrhythmia in 
those with cardiovascular disease (CVD). This is hypothesized to occur through 
stabilization of the myocardial membrane (Chan & Cho, 2009; Dessi, Noce, & Di 
Daniele, 2013). When subjected to ischemia, or restriction of blood supply, 
myocardiocytes allow potassium ions to escape. This increases the resting membrane 
potential and lowers the threshold for initiating an action potential through sodium 
channels, resulting in an increased risk for fatal arrhythmias. Omega-3 fatty acids are 
thought to inhibit sodium channels by increasing the fluidity of the phospholipid bilayer. 
This then reduces membrane excitability and the potential for arrhythmia (Chan & Cho, 
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2009; Dessi, Noce, & Di Daniele, 2013). The studies that have been conducted on this 
theory have been specific to individuals with an implanted cardioverter-defibrillator 
(ICD), or pacemaker. While Raitt et al. (2005) found a non-significantly greater 
incidence of ventricular tachycardia and fibrillation in those receiving 1800 mg fish oil 
versus a placebo (65% versus 59%; p=0.19), Leaf et al. (2005) demonstrated a lower 
incidence in ventricular arrhythmias with 4000 mg fish oil when compared to the placebo 
(28% versus 39%; p=0.057). Furthermore, Calo et al. (2005) randomized 160 patients, 
who were 5 days away from undergoing elective coronary artery bypass, into two groups: 
treatment with 2000 mg fish oil or a placebo. Those in the fish oil group had a 
significantly lower incidence of arrhythmia after bypass when compared to the placebo 
group (15.2% versus 33%; p=0.013). 
Fish oil may have some impact on blood pressure, though its effectiveness as an 
actual therapy for high blood pressure is minimal. EPA and DHA are incorporated into 
the membranes of endothelial cells, increasing fluidity and allowing for improved 
vasodilation through increased nitric oxide production (Chan & Cho, 2009; Dessi, Noce, 
& Di Daniele, 2013). Some research has demonstrated a decrease in heart rate as a result 
of this effect in individuals with high baseline heart rate (Dessi, Noce, & Di Daniele, 
2013). A meta-analysis found a 2.1 mmHg average reduction in systolic blood pressure 
and a 1.6 mmHg average reduction in diastolic blood pressure with a median fish oil 
supplementation of 3700 mg. The greatest reductions were seen in individuals with 
hypertension and in those over the age of 45 (Geleijnse, Giltay, Grobbee, Donders, & 
Kok, 2002). A 3.4/2.0 mmHg reduction in blood pressure was found in those with 
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hypertension with a 5600 mg fish oil dose per day (Morris, M. C., Sacks, F., & Rosner, 
B. 1993). A 5.5/3.5 mmHg blood pressure reduction was seen in untreated hypertensive 
individuals with a fish oil dose of ≥3000 mg per day (Appel, Miller, Seidler, & Whelton, 
1993). DHA seems to have a greater effect than EPA in blood pressure reduction 
andthere does not seem to be a reduction in blood pressure with fish oil supplementation 
for healthy individuals without hypertension (Gazi et al, 2006). 
In a review of four trials, a reduced incidence of secondary cardiac events was 
seen with fish oil supplementation between 1000 and 1800 mg per day or with 1 serving 
of fish per day (Anderson & Ma, 2009). 
The Diet and Reinfarction Trial (DART) focused on secondary prevention of a 
subsequent myocardial infarction (MI; heart attack) with participants who had already 
survived one. In male participants who were recommended to increase their fatty fish 
intake to 7-14 ounces (2.33-4.67 servings) per week and their fish oil intake to 500-800 
mg per day, there was a 29% reduction in mortality from any cause over a 2-year period 
(p < 0.05). There was no difference in the incidence of overall CVD events between those 
who received these recommendations and those who did not. However, there was a 33% 
reduction in fatal MIs when these recommendations were provided (p < 0.01) (Burr et al, 
1989). 
A randomized placebo-controlled prospective study, known as the Indian 
Experiment and Infarct Survival-4 study, examined the use of mustard oil (2900 mg 
ALA) and fish oil (1800 mg EPA and DHA) for secondary prevention in the hospital 
following a suspected acute myocardial infarction. When compared to the placebo group 
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one year later, there was a reduction in total cardiac events and non-fatal myocardial 
infarctions in the mustard oil (p < 0.05) and fish oil (p > 0.01) groups (Singh et al, 1997). 
A meta-analysis of 11 randomized controlled trials found a 27% decrease in fatal 
myocardial infarctions (p < 0.001), a 31% reduction in sudden death (p < 0.01), and a 
19% decrease in mortality from any cause (p < 0.001) with dietary or supplemental EPA 
and DHA intake. It was noted that there was no difference in the occurrence of non-fatal 
myocardial infarctions between groups (Bucher, Hengstler, Schindler, & Meier, 2002). 
Three mechanisms by which EPA and DHA are thought to decrease CVD risk is 
by increasing the fluidity of cellular membranes, decreasing the proportion of the 
membrane occupied by lipid rafts, and modifying the characteristics of these rafts 
(Deckelbaum & Torrejon, 2012). 
Cerebrovascular Disease 
Cerebrovascular disease is defined as a disruption in normal brain function related 
to an abnormality involving the group of blood vessels that supply the brain. Within this 
category are two specific insults to the brain: transient ischemic attack (TIA) and 
cerebrovascular accident (CVA; stroke) (Sonni & Thaler, 2013; Sylaja & Hill 2009). 
A TIA, often called a “mini stroke”, is defined as a temporary obstruction of 
blood flow to the brain that typically lasts only a few minutes but has the tendency to 
recur. A TIA is not usually fatal or permanently damaging on its own. However, it has 
the likelihood of leading to a potentially fatal CVA, or stroke. This is particularly true 
when the episode lasts longer than 10 minutes (Sonni & Thaler, 2013; Sylaja & Hill, 
2009). Approximately 15-20% of individuals who have had a stroke had previously 
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experienced a TIA, usually around three months prior. Research suggests that the early 
window of risk for stroke is 10-15% within ninety days of a TIA (Sylaja & Hill, 2009).  
A cerebrovascular accident (CVA), or stroke, occurs when an artery that provides 
oxygenated blood to the brain is completely obstructed for an extended period of time. 
This leads to damage of the brain tissue and cells and has the risk of resulting in 
functional or cognitive impairment (Sonni & Thaler, 2013). Stroke is the third leading 
cause of death in the United States and is the second leading cause of death worldwide. 
Additionally, it is the first leading cause of long-term disability around the world.  
One-third of individuals die within the first year of having a stroke and more than half are 
unable to recover and regain their independence (Paciaroni & Bogousslavsky, 2010). 
As mentioned previously, stroke falls within the disease class of atherosclerotic 
cardiovascular disease (CVD). Thus, many of the same risk factors for general CVD 
apply to cerebrovascular disease and stroke as well. These include advanced age, 
dyslipidemia, smoking, physical inactivity, hypertension, atrial fibrillation, arterial 
stenosis (specifically of the carotid artery), and diabetes (Paciaroni & Bogousslavsky, 
2010; Sonni & Thaler, 2013; Sylaja & Hill, 2009). 
Fish Oil Supplementation and Cerebrovascular Disease 
 In much the same way that fish oil is thought to reduce cardiovascular disease 
(reduced inflammation, a favorable blood lipid profile, etc.), fish oil is also thought to 
reduce the risk for cerebrovascular disease. Some epidemiological evidence suggests a 
decrease in ischemic cerebrovascular accident (CVA), or stroke, risk with increasing fish 
consumption. It is important to consider, however, that the risk or severity of 
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hemorrhagic stroke may be increased with excessively high doses of fish oil due to the 
potential anticoagulative effect (Gazi et al, 2006). 
Blood Type 
The major blood types in humans are A, B, AB, and O. Of these, A and O are the 
most common. The distinguishing characteristic that places an individual into one of 
these categories is the presence or lack of specific components called antigens. These 
antigens are sugar molecules that are embedded in the cell membrane of erythrocytes, or 
red blood cells. The A antigen is present in blood type A, B antigen in blood type B, A 
and B antigens in blood type AB, and neither of the antigens in blood type O (Ketch et al, 
2008). 
To identify an individual’s blood type, blood is drawn by either a syringe or a 
finger prick. The blood that is collected is placed on a surface in at least two separate 
locations. One sample is mixed with A antibodies and the other is mixed with B 
antibodies. Additional antibodies may be tested in separate samples with some tests to 
further classify blood type. If the blood agglutinates, meaning that the erythrocytes clump 
together, the blood type is not compatible with the antibodies that were added. For 
example, if blood agglutinates when B antibodies are added but not when A antibodies 
are added, the blood type is A. If the blood agglutinates when both A antibodies and B 
antibodies are added, the blood type is O. Blood type B reacts to A antibodies and AB 
blood type reacts to neither. This identification process is known as ABO typing (Flegel, 
2013; Lee, Park, Yang, Lee, & Kim, 2009). 
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Although there are numerous ways to classify blood type, the ABO system is the 
most widely used. It is particularly useful in ensuring the acceptance of foreign tissue; a 
critical consideration in blood transfusion and organ transplant. Unmatched blood type 
triggers an immune response, along with agglutination of the blood within the body 
which can quickly become fatal (Ketch et al, 2008). 
Blood Type and Cardiovascular Disease Risk 
 The blood type of an individual is a strong predictor of hemostasis qualities such 
as clotting time and risk for embolism formation. This is largely due to differences 
between blood types in amounts of von Willebrand factor (vWF) in blood plasma, and 
thus, Factor VIII plasma levels. Both vWF and Factor VIII are considered procoagulant, 
or clot-promoting, agents and are known to increase risk for embolism formation and 
thrombosis. Blood type O has been found to have a reduced coagulability when compared 
to the non-O blood types A, B, and AB (Dentali, Sironi, Ageno, Crestani, & Franchini, 
2014; Ketch et al, 2008; Souto et al, 2000). Non-O blood type indicates that levels of 
these factors are about 25% higher than those associated with the blood type O. It has 
been established that individuals with non-O blood type are at an increased risk for 
developing a venous thromboembolism when compared to blood type O. There is also a 
recently discovered positive association, though it is weak, between non-O blood type 
and risk for arterial thrombotic events. These events include myocardial infarctions (MI; 
heart attack), ischemic cerebrovascular accidents (CVA; stroke), and muscle ischemia 
(Dentali et al, 2014; Ketch et al, 2008). 
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In individuals who have experienced an MI, the amount of risk estimated to be 
conferred by non-O blood type is approximately 9.7%. A systematic review by found a 
consistent relationship between non-O blood type and increased likelihood for an MI 
(Wu, Bayoumi, Vickers, & Clark, 2008). A large meta-analysis by He et al. (2012) 
demonstrated that those with a non-O blood type were 11% more likely to develop 
coronary heart disease (CHD) when compared to O blood type individuals. There was 
also a significantly greater proportion of non-O blood type in those who had experienced 
an MI, when compared to blood type O. 
The evidence in support of the association between ABO blood type and ischemic 
CVA, or stroke, is less conclusive. A large case-control study by Hanson et al did not 
find a link between ABO blood type and ischemic stroke risk. On the other hand, the 
meta-analysis by Wu, Bayoumi, Vickers, & Clark found a slight but significant 
association between these variables (2008). Although there appears to be a slightly 
increased risk for ischemic stroke with non-O blood type, the relationship is not well-
supported and thus additional research is needed to confirm it (Dentali et al, 2014). 
Fish Oil Supplementation and Blood Type 
Fish oil is considered to be an antithrombotic substance, meaning that adequate 
fish oil intake is associated with reduced tendency for blood clotting and coagulation. 
This occurs through suppression of platelet cyclooxygenase metabolism, thus reducing 
thrombin-stimulated platelet aggregation (Keenan, Pedersen, & Newman, 2012). Based 
on this characteristic, it is expected that fish oil supplementation will mitigate the 
heightened tendency for blood clotting and thrombosis in non-O blood type. 
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Insulin 
 Insulin is an anabolic polypeptide hormone that is produced by the β-cells in the 
pancreas (Islets of Langerhans). It is released into the blood in response to consumption 
of a meal containing glucose, the main source of energy within the body (Triplett, 2012). 
From the pancreas, insulin travels in the blood to cells in need of glucose. Every cell 
possesses insulin receptors which are embedded within the cell membrane but are 
accessible outside of the cell. Insulin itself never actually enters the cell; it only binds to 
these insulin receptors on the outside of the cell. This activates a secondary messenger 
system which results in the uptake of glucose into the cell via specialized transport 
proteins in the membrane, such as GLUT-1 and GLUT-4. Plasma glucose concentrations 
are reduced as a result (Seino, Shibasaki, & Minami, 2011; Triplett, 2012). The glucose 
transported into the cell is then assembled into chains which create the storage form of 
glucose known as glycogen (Triplett, 2012). Beyond its function to bring glucose into 
cells, insulin has additional functions within the body. One other function that it carries 
out is the inhibition of hepatic glycogen breakdown to glucose. Also, it prevents the 
breakdown of lipids from adipose tissue, a process called lipolysis (Kalupahana, 
Claycombe, & Moustaid-Moussa, 2011). 
Insulin resistance 
 Insulin resistance is defined by a lack of response or an inadequate response in 
cells which are normally quite sensitive to insulin. These cells include hepatocytes, 
skeletal myocytes, and adiopocytes (Kalupahana, Claycombe, & Moustaid-Moussa, 
2011). One example of insulin resistance arises when insulin is unable to bind insulin 
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receptors on the outer membrane of cells. Another scenario in which a person would be 
considered insulin resistant is when insulin binds the receptor but the transport of glucose 
into the cell is defective. When cells are resistant to insulin, glucose is unable to enter the 
cell and it remains in the plasma. As a result, plasma glucose concentrations become 
elevated and the cells are starved of glucose (Seino, Shibasaki, & Minami, 2011). If this 
goes on for an extended amount of time, weight loss occurs and the body resorts to 
another source of energy known as ketones. Weight reduction, exercise, and certain 
medications can reduce insulin resistance (American Diabetes Association, 2010). To 
detect insulin resistance, two simple equations are used: the homeostatic model 
assessment (HOMA-IR) and the QUICKI. HOMA-IR is a direct measure of insulin 
resistance. An increased HOMA-IR score means that insulin resistance is increased. A 
score >1 is considered abnormal and a sign of insulin resistance (Matthews et al, 1985; 
Muniyappa, Lee, Chen, & Quon, 2008). QUICKI, on the other hand, is a measure of 
insulin sensitivity rather than insulin resistance. Therefore, a decreased QUICKI score 
would indicate increased insulin resistance. A score <0.375 is abnormal and implies that 
an individual is insulin resistant (Muniyappa et al, 2008). 
Characteristics of Diabetes Mellitus 
Diabetes mellitus (DM) is a metabolic disorder that is indicated by high glucose 
concentration in the blood (hyperglycemia). In type 1 diabetes mellitus (T1DM), the 
pancreatic β-cells are no longer to produce insulin which leaves the individual completely 
dependent on exogenous insulin via injections (Bhattacharya, Dey, & Roy, 2007). 
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The form of diabetes mellitus that this study is interested in, type 2 diabetes 
mellitus (T2DM), is the most common form with it being 90-95% of cases (Bhattacharya, 
Dey, & Roy, 2007). Those with T2DM are typically not fully dependent on insulin, 
though they may need it to maintain adequate glucose control. In T2DM, the pancreatic     
β-cells still produce insulin. However, the cells in the body tend to be resistant to the 
insulin that is produced which results in hyperglycemia. In response to this, the 
pancreatic β-cells produce more insulin to compensate for the insulin resistance. Over 
time, the pancreas can become fatigued in a sense and its production of insulin may 
actually decrease. At this point, exogenous insulin with the possible addition of  
insulin-stimulating or insulin-sensitizing medications may be indicated (American 
Diabetes Association, 2010; Kalupahana, Claycombe, & Moustaid-Moussa, 2011). This 
disease process can be a product of genetic predisposition, lifestyle factors, and 
environmental exposure. This form of diabetes tends to occur more often in those who 
are obese but it can also occur in normal weight individuals, particularly in those who 
have excess abdominal adiposity (Triplett, 2012). 
Excess glucose in the blood causes oxidative damage to cells and tissues. Damage 
to the micro- and macrovasculature can occur and existing atherosclerosis can be 
aggravated by excessive levels of glucose in the blood (Triplett, 2012). The small blood 
vessels that travel through the kidneys and retina of the eye are often damaged easily by 
this oxidative effect. Thus, renal failure and impaired vision are common findings in 
uncontrolled diabetes (American Diabetes Association, 2010; Triplett, 2012). When 
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insulin cannot bring glucose into cells, those cells must resort to other sources of energy. 
Most often, lipids are broken down in response to this need (Triplett, 2012). 
Classic symptoms of untreated hyperglycemia include increased thirst 
(polydypsia), increased appetite (polyphagia), increased urination (polyuria), weight loss, 
blurred vision, and recurrent infections (American Diabetes Association, 2010). These 
symptoms are often the first sign of the condition and must be present for diagnosis, 
along with an elevated fasting or casual glucose concentration. The diagnosis of diabetes 
mellitus is confirmed with an oral glucose tolerance test (OGTT) in which an individual 
who has been fasting for at least 12 hours drinks a solution with a 75 g glucose load. The 
diabetic individual has a fasting plasma glucose (FPG) concentration of ≥126 mg/dL. The 
concentration at two hours after consuming the solution is ≥200 mg/dL for the person to 
be considered diabetic (Roumen, Feskens, Jansen, Saris, & Blaak, 2008). To diagnose 
diabetes and assess long-term glycemic control (over the past 120 days), a test known as 
hemoglobin A1C can be run. This is measurement of the amount of glycation on 
hemoglobin in erythrocytes (red blood cells). A hemoglobin A1C reading of ≥6.5% is the 
diagnostic cut-off value (American Diabetes Association, 2010). 
Type 2 Diabetes Mellitus 
T2DM is diagnosed when the classic symptoms of diabetes mellitus are present in 
addition to having an hemoglobin A1C ≥6.5% or a casual blood glucose concentration of 
≥200 mg/dL (American Diabetes Association, 2010). The diagnosis can then be 
confirmed with an OGTT if indicated. For those with T2DM, insulin in the blood is 
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usually normal or it may even be elevated. The absence of antibodies against insulin or 
pancreatic β-cells will verify that it is not T1DM (American Diabetes Association, 2010). 
In many cases of T2DM, weight loss or exercise helps to stabilize glycemic 
control without the need for further intervention. However, the need for oral  
glucose-lowering medication is often indicated. Depending on the nature and severity of 
the disease, an individual with T2DM may or may not be dependent on insulin injections 
to maintain good glycemic control. Unlike those with T1DM, these individuals produce 
at least some insulin so that they can survive without exogenous sources if necessary 
(American Diabetes Association, 2010). 
Prediabetes 
There is a state of defective glucose metabolism at a level that is not yet able to be 
diagnosed as diabetes mellitus. This is known as prediabetes, which indicates that an 
eventual progression to full-blown T2DM may develop if adequate intervention does not 
occur. The two categories of prediabetes are impaired fasting glucose (IFG) and impaired 
glucose tolerance (IGT). As in the diagnosis of diabetes mellitus, these conditions are 
assessed using an OGTT (American Diabetes Association, 2010). In IFG, the individual 
has a fasting plasma glucose (FPG) above the normal level at ≥100 g/dL but lower than 
the level indicating diabetes of <126 mg/dL. At two hours after consuming a glucose 
load, those with IGT have a plasma glucose concentration greater than the normal level at 
≥140 mg/dL but less than the level indicating diabetes of <200 mg/dL. The diagnostic 
hemoglobin A1C level for prediabetes is ≥6.0% and ≤6.5%. Like diabetes mellitus, 
prediabetes is often connected to obesity and abdominal adiposity (American Diabetes 
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Association, 2010). It is important to recognize that, at this point, any disruptions of 
normal metabolism are still considered largely reversible (Liu et al, 2009). Therefore, 
early detection and effective intervention are imperative. The same general treatment 
methods for managing diabetes apply to reversing prediabetes as well. Weight loss, 
increased physical activity, and certain medications can help to prevent or at least 
postpone the progression of prediabetes into diabetes mellitus (American Diabetes 
Association, 2010; Mensink et al, 2003). 
Diabetes Mellitus and Cardiovascular Disease Risk 
 Due to the damaging effect of high blood glucose levels, individuals with diabetes 
mellitus are at an increased risk for developing cardiovascular disease (CVD) when 
compared to individuals without diabetes. Thus, CVD is a common cause of morbidity 
and mortality in those with diabetes mellitus. The degree of severity also tends to be 
higher when diabetes mellitus is involved (Polidori, 2003; Voulgari, Papadogiannis, & 
Tentolouris, 2010). Both T1DM and T2DM present an increased risk for developing 
CVD. Uncontrolled and prolonged hyperglycemia leads to oxidative damage of the 
vasculature system, resulting in the complications known to be associated with diabetes 
mellitus. These include aggravated atherosclerosis, kidney damage (nephropathy), nerve 
damage (neuropathy), and retinal damage (retinopathy). With regards to cardiovascular 
disease risk, atherosclerosis is of particular concern. Monitoring and controlling blood 
glucose levels, with or without medication and insulin, is the most effective way to 
prevent such complications (American Diabetes Association, 2010; Polidori, 2003; 
Triplett, 2012). 
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An increased risk for cardiovascular disease translates to an increased risk for 
transient ischemic attack (TIA) and cerebrovascular accident (CVA; stroke). One 
population-based study with a 20-year follow up revealed that 27% of individuals who 
had T2DM had experienced a stroke. Interestingly, stroke tends to be more severe in 
those with diabetes than in those without diabetes. Tight control of blood glucose levels 
appears to be critical to preventing stroke in this population (Samson, 2010). 
Fish Oil Supplementation and Diabetes Mellitus 
Some research suggests that fish oil supplementation may have an insulin 
sensitizing effect. The mechanism by which this is thought to occur is related to the 
incorporation of EPA and DHA into the cellular membrane, thereby increasing its 
fluidity. This then increases the number of insulin receptors that can be incorporated into 
the membrane, allowing increased opportunity for insulin to bind and act on a cell. This, 
in turn, has the potential to decrease insulin resistance (Anderson & Ma, 2009). 
Another potential benefit from fish oil with regards to diabetes is related to the 
cardiovascular aspect of diabetes management. When the endothelial cells of the 
vasculature are subjected to hyperglycemia, a transcription factor known as nuclear factor 
kappa B (NF-kb) is upregulated. It appears that EPA and DHA act to downregulate this 
factor and, as a result, may reduce the vascular damage from the chronically elevated 
levels of blood glucose that are often found in those with diabetes (Anderson & Ma, 
2009). 
An additional component of insulin resistance and diabetes in which fish oil 
supplementation may have an effect is proliferator-activated receptor gamma (PPARγ). 
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PPARγ is responsible for increasing the expression of GLUT-1 and GLUT-4 which 
increases glucose uptake by adipocytes and myocytes. EPA and DHA act as ligands for 
PPARγ to promote its function and decrease levels of glucose in the blood. This 
activation of PPARγ has the secondary effect of inhibiting the expression of insulin 
resistance-promoting cytokines. This then increases plasma levels of adiponectin, a 
hormone that promotes insulin sensitivity and reduces hepatic glucose release (Anderson 
& Ma, 2009; Kalupahana, Claycombe, & Moustaid-Moussa, 2011). Additionally, 
adiponectin acts to increase the breakdown of lipids. This may reduce the inflammatory 
consequences that can arise with excess adipose tissue (Kalupahana, Claycombe, & 
Moustaid-Moussa, 2011).  By these pathways, EPA and DHA appear to have an anti-
diabetic influence (Anderson & Ma, 2009; Kalupahana, Claycombe, & Moustaid-
Moussa, 2011).  
Despite the evidence of these numerous mechanisms, there is limited research 
regarding the effect of fish oil supplementation on insulin sensitivity and the findings are 
not consistent. In one study, healthy participants were asked to eliminate 6000 mg of 
visible fat from their diet and add 6000 mg of fish oil. This resulted in decreased body fat 
mass and increased lipid oxidation within the body. Another study by Browning et al. 
(2007) demonstrated that supplementation with fish oil increased insulin sensitivity in 
overweight women, though it is not clear whether reduced inflammation was a mediating 
factor. Yet another study did not find any beneficial effect for insulin sensitivity with fish 
oil supplementation (Kusunoki et al, 2007). It appears that the benefit of increased insulin 
sensitivity may be limited to healthy non-diabetic individuals. Based on this information, 
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the use of fish oil supplementation could potentially provide some benefit by preventing 
the development or delaying the onset of prediabetes and T2DM (Anderson & Ma, 2009). 
Fish Oil Supplementation and Obesity 
Conventional treatment for obesity involves encouraging a healthy, reduced-
energy diet and regular participation in physical activity. For many individuals however, 
these lifestyle modifications can be very difficult to initiate and maintain. Research 
suggests that EPA and DHA, the long-chain omega-3 fatty acids found in fish oil 
supplementation, may be associated with reduced risk for obesity (Buckley & Howe, 
2010). 
The reduction in risk for obesity is thought to be due to the function of EPA and 
DHA in suppressing appetite, encouraging the development of lean tissue, increasing 
oxidation of lipids, and reducing deposition of lipids into adipose tissue. These metabolic 
changes have been shown to occur in rodents and humans, though there is limited 
evidence to demonstrate an actual reduction in obesity for humans. It has been 
hypothesized that the increase in lean tissue accumulation and maintenance is a result of 
enhanced blood circulation. This is thought to contribute to improved distribution of 
nutrients to skeletal muscle tissue, allowing the tissue to receive the substrates it needs to 
maintain function. There is also some evidence to suggest that EPA reduces the activity 
of the proteolytic ubiquitin-proteasome pathway, thus suppressing the catabolism 
(breakdown) of muscle tissue (Whitehouse & Tisdale, 2001; Wing & Goldberg, 1993; 
Wyke & Tisdale, 2005). Additionally, muscle anabolism (building) may be enhanced 
through EPA’s upregulation of the kinases mTOR and S6K which are involved in muscle 
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protein synthesis (Gingras et al, 2007). The enhancement of lipid oxidation has been 
linked to an upregulation of mitochondrial carnitine palmitoyl transferase I (CPT-I). This 
enzyme is involved in the transport of fatty acids into the mitochondria for oxidation. The 
reduction of lipid deposition into adipose tissue is thought to be a result of decreased 
levels of serum triglycerides (Buckley & Howe, 2010). 
Research with rodents has explored the addition of EPA and DHA to a high-fat, 
obesogenic diet. There is some evidence showing a reduction lipid deposition with this 
feeding method. Unfortunately, the results of studies on this topic have not been fully 
consistent. Several studies with rodents who had diabetes actually demonstrated an 
increase in body weight when fed the high-fat diet with supplementation of EPA and 
DHA (Baillie, Takada, Nakamura, Clarke, & 1999; Belzung, Raclot, & Groscolas, 1993; 
Cunnane, McAdoo, & Horrobin, 1986; Hainault, Carlotti, Hajduch, Guichard, & Lavau, 
1993; Ruzickova, 2004). Nevertheless, this was not seen in rodents without diabetes 
(Todoric et al, 2006). Since body fat was not measured in these studies, however, it is 
uncertain whether the differences in weight were in fact due to changes in body fat 
accumulation (Buckley & Howe, 2010). 
Perhaps, EPA and DHA may be more efficient in preventing obesity in normal 
weight individuals and reducing further accumulation of adipose stores in those who are 
already obese (Buckley & Howe, 2010). It is also worth recognizing that EPA and DHA 
have been shown to reduce levels of inflammation that are associated with high amounts 
of adipose stores (Kalupahana, Claycombe, & Moustaid-Moussa, 2011). Additionally, 
research suggests that fish oil may encourage a more favorable distribution of body fat. 
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Visceral (epididymal) fat, also referred to as abdominal adiposity, is associated with 
greater levels of inflammation, insulin resistance, and dyslipidemia (Athyros, Tziomalos, 
& Mikhalidis, 2011; Klop & Cabezas, 2013). Evidence from rodent studies has shown a 
reduction in visceral fat stores with fish oil supplementation. DHA appears to have a 
more profound impact than EPA in this particular phenomenon (Buckley & Howe, 2010). 
Some evidence suggests an enhanced improvement in body tissue composition may occur 
when EPA and DHA are added to a reduced-energy diet, exercise regimen, or 
combination of the two. Interestingly, the changes seen in body weight and body 
composition appear to occur independently of energy intake (Buckley & Howe, 2010). 
Though a reduction in actual amount of adipose tissue may not occur, these changes may 
potentially reduce the risk for comorbidities associated with obesity such as 
cardiovascular disease (CVD) and diabetes (Buckley & Howe, 2010; Kalupahana, 
Claycombe, & Moustaid-Moussa, 2011).  
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Chapter 3 
METHODS 
Participant Recruitment 
 This 8-week study was a randomized, double-blinded, and placebo-controlled 
trial.  Male and female adults, 18 to 50 years of age and generally healthy, were recruited 
for the present study. Participants were recruited starting in November 2013 using an 
advertising email sent out via a listserve which contained a link to a web-based 
questionnaire. After this initial screening process twenty-four participants, eight male and 
sixteen females, were enrolled on the basis of the following criteria: in good general 
health, 18-50 years old, no current or recent use of fish oil supplements (within the past 2 
months), no heavy use of cigarettes (>10 cigarettes daily), no excessive physical activity, 
non-vegetarian diet, not lactating or pregnant, and not allergic to fish, nuts, or soy 
products. Six females and one male belonged to blood type A. Seven males and ten 
females belonged to blood type O. Approximately 26% of the individuals who responded 
to the initial advertisement fulfilled these criteria and volunteered to participate in the 
study (24 of 92 total respondents). 
Exclusion was based on the following criteria: 1) blood type other than A or O, 2) 
current or past pharmaceutical treatment for cardiovascular disease, 3) regular 
consumption of more than two 3.5 ounce servings of fish per week, 4) underweight 
(BMI<18.5 kg/m
2
) or obesity (BMI >35 kg/m2), and 5) use of prescription medication 
that may influence body weight (thyroid medication, corticosteroids, or NSAIDS).  
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Participants were instructed maintain their diet and exercise habits during the study 
period. They were also asked to report any new medical diagnoses or medication use. 
Participants came in for 3 visits over the span of about 2 months. The study was 
completed January 2014. Informed consent was obtained in writing after the purpose, 
nature, and potential risks were explained to the participants. The experimental protocol 
was approved by the Institutional Review Board at Arizona State University. 
Prestudy Qualification 
Following the initial screening using the answers from the online questionnaire, 
eligible participants were asked to come to the university laboratory for further 
assessment of eligibility (Visit 1). After obtaining informed consent, all participants were 
asked to fill out a health history questionnaire which addressed demographic 
characteristics, smoking habits, alcohol intake, eating and exercise habits, and current 
medication use. Height, weight, waist circumference, and body fat (Tanita bioelectrical 
impedance scale) were measured and recorded. Body mass index (BMI) was calculated 
as weight (in kilograms) divided by height (in meters) squared. Participants also 
completed a food frequency questionnaire that has been validated for approximating an 
individual’s typical omega-3 fatty acid intake (Ritter-Gooder, Lewis, Heidal, & Eskridge, 
2006). If found to be ineligible based on the exclusion criteria, participants were released 
from the study. Using a finger prick, a small sample of blood was used to assess blood 
type (EldonCardTM 2511-1 ABO-Rh Home Blood Typing Test Kit). If participants were 
a blood type other than A or O, they were released from the study. If the participants 
were blood type A or O, they were entered into the study and scheduled for visit #2. 
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At visit #2, venous blood sample was taken from an arm vein (<2 Tbsp). Blood 
was processed and used for immediate analyses or frozen (-80°) for future analyses. The 
markers of interest were hemoglobin A1C (HbA1C), high sensitivity C-reactive protein 
(hsCRP), and serum lipids. Blood clotting times were also assessed for a companion 
study.  Participants were stratified by age, BMI, weight, blood type, fish consumption and 
gender and then randomized to one of two groups:  fish oil supplementation (FO; n=13) 
or coconut oil supplementation (CO; n=11). In the fish oil supplementation group, 9 were 
female (3 blood type A, 6 blood type O) and 4 were male (1 blood type A, 3 blood type 
O). In the coconut oil supplementation group, 7 were female (3 blood type A, 4 blood 
type O) and 4 were male (4 blood type O, 0 blood type A). Participants were instructed to 
ingest 2 capsules daily (fish oil, 1000 mg with an EPA:DHA ratio of 4:2, or coconut oil, 
1000 mg) for the course of the 8 week trial. 
Table 3. Fatty Acids in Two 1000 mg EnergyFirst OmegaEnergy Fish Oil Supplements 
Fatty acid Content of Two 1000 mg capsules 
Eicosapentanoic acid 800 mg 
Docosahexanoic acid 400 mg 
 
Table 4. Fatty Acids in Two 1000 mg Puritan’s Pride Organic Coconut Oil Supplements 
Fatty acid Content of Two 1000 mg capsules 
Lauric acid 1760 mg 
Myristic acid 520 mg 
Caprylic acid 212 mg 
Palmitic acid 300 mg 
Capric acid 180 mg 
Oleic acid 200 mg 
Stearic acid 40 mg 
Linoleic acid 40 mg 
 
For additional Supplement Facts details, please reference page 88. 
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Participants were given enough capsules of their assigned supplements to take one 
each day until the next scheduled visit. Calendars were provided with instruction to note 
days that supplements were taken.  
Eight weeks later, participants came in for the final visit (Visit 3). This involved a 
second venous blood draw from an arm vein (<2 Tbsp). The blood was again processed 
and used for immediate analyses or frozen (-80°) for future analyses. The same 
anthropometric measurements were taken as in Visit 1. Twenty-four hour recalls were 
collected from participants at the final visit for the companion study. The same markers 
were assessed as in the previous blood draw. Supplement adherence was determined 
using the days marked off on participants’ calendars. 
Study timeline 
 
 
 
 
Screening 
(Visit 1) 
-Informed consent 
-Health history questionnaire 
-Food frequency questionnaire 
-Blood type check 
Baseline - Week 0 
(Visit 2) 
-First venous blood 
sample to assess 
baseline biomarkers                             
-Distribute supplements 
Week 8 
(Visit 3) 
-Post-intervention  
-Second venous blood sample 
-Pill count and calendar check 
-24 hour recall 
-Debriefing 
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Laboratory Analyses 
At baseline (week 0) (Visit 2) and week 8 (Visit 3), all participants returned to the 
study laboratory and venous blood (2 Tbsp) was collected. The blood samples were 
assessed for cardiovascular biomarkers and long-term glucose control. The samples were 
casual, meaning that they were not specifically taken in a fasting state. The measurement 
of cholesterol (TC, HDL-C, LDL-C, and VLDL-C) does not require fasting blood for 
accuracy. The serum TG measurement, however, is most meaningful when fasting blood 
is used. Blood lipids were assessed using Piccolo. Piccolo directly measures total TC, 
TG, and HDL-C. The machine calculated VLDL-C is by dividing TG by 5 and LDL-C 
was calculated by the machine using the Friedewald equation (LDL-C = TC - (HDL-C + 
TG/5)). Therefore, in this case, LDL-C and VLDL-C measurements were impacted by 
the state of fasting. Hemoglobin A1C was assessed using DCA Vantage Analyzer (Model 
2000) and hsCRP was assessed using COBAS methodologies (model). 
Statistical Methods 
 Statistical analyses were performed using the SPSS Statistical Analysis system 
22.0. Before statistical analysis was conducted, normal distribution and homogeneity of 
the variances were statistically tested. A 2-way ANOVA was run using univariate 
analyses to determine the effects of treatment and blood type on the outcome measures. 
Data are expressed as mean ± standard deviation.  Significant difference within- or 
between-groups was defined as P < 0.05. A large effect size was defined as ≥0.2. 
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Chapter 4 
RESULTS 
Eight men and 16 women were enrolled in the study and randomized to treatment 
groups (26.1±8.6 y; 25.2±3.6 kg/m
2
). Two participants never started the study, and an 
additional 4 participants did not complete the 8-week trial. Two of these individuals 
withdrew for medical reasons that were unrelated to the study protocol. The remainder of 
the participants was lost to attrition (reason unknown). A blood sample could not be 
collected from one of the completing participants; hence, blood data are only available 
for 17 participants. There were no significant differences by gender, age, BMI, or blood 
type for those that did and those that did not complete the study (data not shown). The 
data presented below are for only the 17 participants completing the study for which 
blood data were available.   
The fish oil supplementation group had 10 participants. Of these, 7 were female 
(2 blood type A, 5 blood type O) and 3 were male (1 blood type A, 2 blood type O). 
There were 7 participants in the coconut oil supplementation group. Of these, 4 were 
female (3 blood type A, 1 blood type O) and 3 were male (0 blood type A, 3 blood type 
O).  
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As shown in Table 5, the age of the participants ranged from 22 to 47 years old 
for individuals with blood type A and 18 to 44 years old for those with blood type O. 
Baseline weight for blood type A individuals ranged from 132 to 192 pounds and 131 to 
250 pounds for blood type O individuals. Height for blood type A 167 to 179 centimeters 
blood type O ranged from 168 to 192 centimeters.  Baseline body mass index (BMI) for 
blood type A ranged from 20 to 28 kg/m
2
 and for blood type O, BMI ranged between 
21and 31 kg/m
2
. Physical activity (PA) at baseline ranged from 31 to 128 metabolic 
equivalents (METS) and from 19 to 83 metabolic equivalents (METS) for blood type A 
and blood type O individuals respectively. Omega-3 (n-3) fatty acid intake at baseline 
was 0.16 to 2.24 grams in those with blood type A and 0.03 to 1.74 grams per day in 
those with blood type O. Baseline total cholesterol (TC) ranged from 124 to 266 mg/dL 
in those with blood type A and 95 to 282 mg/dL in those with blood type O. Baseline 
low-density lipoprotein cholesterol (LDL-C) was 39 to 179 mg/dL with blood type A and 
43 to 166 mg/dL with blood type O. Baseline high-density lipoprotein (HDL-C) was 51 
to 78 mg/dL in blood type A and 28 to 80 mg/dL in blood type O. Baseline triglyceride 
(TG) ranged from 35 to 281 mg/dL in blood type A individuals and 46 to 434 mg/dL in 
blood type O individuals. Baseline hemoglobin A1C (HbA1C) was 4.8 to 5.6 percent 
with blood type A and 4.9 to 5.6 percent with blood type O. Baseline C-reactive protein 
(CRP) for blood type A was 0.15 to 7.11 and 0.17 to 3.96 for blood type O. 
As shown in Table 5, there was no association or interaction between blood type 
and group for age, weight, body mass index (BMI), physical activity (PA), omega-3 (n-3) 
fatty acid intake, TC, LDL-C, HDL-C, serum TG, HbA1C, or hsCRP. 
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For the fish oil supplementation group, the percent change in weight for blood 
type A individuals ranged from -1% to +4% and -9% to +5% for blood type O 
individuals. Percent change in percent body fat ranged from -1% to +1% for blood type A 
and -14% to +8% for blood type O. Percent change in TC ranged from -9% to +3% for 
individuals with blood type A and -21% to +15% for individuals with blood type O. 
Percent change in LDL-C for blood type A ranged from -13% to +23% and O ranged 
from -25% to +15% Percent change in HDL-Cfor blood type A ranged from -13% to 
+2% and for blood type O, from -17% to +16%. Percent change in serum TG ranged 
from -19% to +77% for those with blood type A and -41% to +29% for those with blood 
type O. Percent change in HbA1C for blood type A ranged from -11% to -2% and for 
blood type O, from -6% to +9%. Percent change in hsCRP ranged from -90% to +147% 
for individuals with blood type A and -53% to +443% for individuals with blood type O.  
For the coconut oil supplementation group, the percent change in weight for blood 
type A individuals ranged from -5% to 0% and -3% to +2% for blood type O individuals. 
Percent change in TC ranged from -19% to +3% for individuals with blood type A and -
26% to +19% for individuals with blood type O. Percent change in LDL-C for blood type 
A ranged from -32% to +1% and for blood type O, from -25% to -5%. Percent change in 
HDL-C for blood type A ranged from -3% to +11% and for blood type O, from -34% to 
+32%. Percent change in serum TG for blood type A individuals ranged from -16% to 
0% and -17% to +64% for those with blood type O. HbA1C ranged from -2% to +2% for 
those with blood type A and -8% to +6% for those with blood type O. Percent change in 
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high-sensitivity hsCRP ranged from +25% to +127% in those with blood type A and -
81% to +197% in those with blood type O. 
As shown in Table 6, there was a significant difference in percent change in  
LDL-C between treatment groups (p=0.048).There were no significant  associations or 
interactions for blood type and group and percent change in weight, body fat, TC, HDL-
C, TG, HbA1C, or hsCRP. 
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Chapter 5 
DISCUSSION 
 This study represents a randomized, double-blind comparison of four groups of 
healthy individuals: one with blood type A that consumed fish oil supplements, one with 
blood type A that consumed coconut oil supplements, one with blood type O that 
consumed fish oil supplements, and one with blood type O that consumed coconut oil 
supplements. The impact of group and/or blood type for cardiovascular disease markers 
was examined. The biomarkers examined were total cholesterol (TC), low-density 
lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), serum 
triglycerides (TG), hemoglobin A1C (HbA1C), or high-sensitvity C-reactive protein 
(hsCRP). All are well established as indicators of cardiovascular disease risk. 
 The data show that after 8 weeks of coconut oil supplementation, a significant 
reduction in LDL-C was observed compared to the fish oil supplement treatment but this 
difference was not impacted by blood type. Conversely, there was a significant increase 
in LDL-C for blood type A after 8 weeks of fish oil supplementation. There was no 
significant change in weight, body fat, HDL-C, TC, serum TG, HbA1C, hsCRP in either 
blood type A or O with use of fish oil supplements. 
 The supplemental form of coconut oil has been used in several past studies that 
have also examined fish oil supplementation. Dosing was similar, if not identical, to that 
used in the current study (2000 mg/day). At this time, there has not been a documented 
change in the blood lipid profile when coconut oil is used in this manner. Its use in 
research has been quite limited, however, and many of the studies in which it has been 
58 
 
used have not actually measured blood lipids (Amminger et al, 2013; Karr, Grindstaff, & 
Alexander, 2012; Mozaffari-Khosravi, Yassini-Ardakani, Karamati, & Shariati-Bafghi, 
2013; Trepanowski, Kabir, Alleman, & Bloomer, 2012). Aside from the supplemental 
form, the dietary form of coconut oil has been studied for its impact on health. This 
tropical oil is known to be quite high in saturated fatty acids (90%) (Palazhy et al, 2012). 
However, the majority of these are medium-chain length (65%), meaning that they are 
absorbed directly into the bloodstream and transported to the liver. Medium-chain 
saturated fatty acids are metabolized by the liver to provide energy, while other fatty 
acids would be used for lipoprotein synthesis (DebMandal & Mandal, 2011). Because of 
this, it has been suggested that coconut oil should have a neutral impact on blood lipids. It 
has been proposed that a beneficial effect may be seen when coconut oil replaces other 
forms of saturated fat, along with trans fats. Some past studies that have demonstrated an 
adverse effect of coconut oil on lipid profiles have been critiqued for using a 
hydrogenated form of the oil (Kintanar, 1988). Studies that have used a non-
hydrogenated supplemental form have shown modest favorable changes in blood lipids. 
Animal studies have shown a decrease in total cholesterol and lipoproteins with coconut 
oil supplementation (Feranil, Duazo, Kuzawa, & Adair, 2011). Nevertheless, much of the 
research on coconut oil has focused on its use as part of the diet rather than as a 
nutritional supplement. Many studies have been non-experimental and have merely 
assessed the impact of individuals’ current dietary habits (i.e. cooking with coconut oil 
versus cooking with another oil) (Feranil, Duazo, Kuzawa, & Adair, 2011; Palazhy et al, 
2012). Also, these studies have involved the use of coconut oil in relatively large 
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amounts; some as high as 20% of total kilocalories (Nevin, 2008). Participants in the 
current study were only asked to take a daily dose of 2000 mg coconut oil and this was 
not intended to replace other fat in the diet. It is likely that the observed decrease in LDL-
C was due to extraneous factors, such as sample size and lifestyle changes. Further 
exploration of this potential association is warranted. 
Previous literature has shown that fish oil supplementation increases blood levels 
of LDL-C. While this would typically be considered an undesirable effect, it has been 
shown that the LDL particles become larger and more buoyant with fish oil use. These 
qualities make the LDL particles less atherogenic, or less likely to contribute to 
atherosclerosis (Chan & Cho, 2009; Dessi, Noce, & Di Daniele, 2013; Gazi et al, 2006). 
A significant increase in LDL-C was demonstrated in the current study, as expected 
based on this literature. 
The EPA and DHA content of the fish oil supplements taken by participants was 
600 mg per capsule. The capsules were to be taken twice a day to provide a total daily 
dose of 1200 mg EPA and DHA. According the United States Department of Agriculture 
(USDA), high omega-3 fish contain approximately 407 mg of EPA and DHA per ounce 
(2004). Using this information, it can be determined that the participants in this study 
consumed the equivalent of 20.6 ounces of high omega-3 fish per week. That is equal to 
five 4-ounce servings per week, or seven 3-oz servings per week. Based on previous 
literature, this dosing is adequate to produce a modest observable change in blood lipids. 
The current study was limited by a small and relatively uniform sample. The 
majority of the participants (22 of 24; 92%) in the study identified themselves as 
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Caucasian. The others (2 of 24; 8%) identified themselves as Hispanic. Because the 
Hispanic individuals resigned from the study before blood could be drawn, it is unclear 
whether ethnicity could have influenced the results of this study. This resulted in an 
ethnically homogenous sample (100% Caucasian). When considering those who 
completed the study, it is important to note that females were overrepresented in the 
sample (65%; 11 of 17), along with those who had blood type O (65%; 11 of 17). Age 
may have been a factor as well, given that the majority (82%; 14 of 17) of the participants 
was between the ages of 18 and 36 years old. Also, the length of time that the 
supplements were taken was relatively short. It may take several months for significant 
changes in blood lipids and hemoglobin A1C to occur. Another consideration is that past 
literature has demonstrated a more dramatic change in triglycerides when they are 
abnormally high. The current study’s participants did not have very high serum 
triglyceride levels (<500 mg/dL). Additionally, the blood draws were not specifically 
taken in a state of fasting. The number of participants who were and were not fasting is 
unknown, Although it has been shown that fasting blood is not necessary for measuring 
total cholesterol and lipoproteins, it is necessary for serum triglycerides which can vary 
depending on recent lipid intake. Further research studies with larger and more diverse 
samples may yield statistical significance, whereas the current study only shows trends 
for change in many parameters. 
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Chapter 6 
CONCLUSION AND RECOMMENDATIONS 
Conclusion 
 Aside from aforementioned increase in low-density lipoprotein (LDL) for blood 
type A, the results of the current study did not demonstrate a significant difference in 
cardiovascular disease markers between blood types A and O after consuming fish oil 
supplements relative to coconut oil supplements. However, the effect of fish oil 
supplementation on markers of cardiovascular disease, without consideration for blood 
type, has been thoroughly researched and documented in past studies. It is then feasible 
that a larger and more diverse sample may be enough to show a more definitive 
difference. 
Recommendation 
 Additional research that further explores the topic at hand is recommended to 
improve understanding of fish oil’s influence on cardiovascular disease risk for blood 
types A and O. Recruiting a larger and more diverse sample will be necessary to draw a 
stronger conclusion that can be generalized. It is recommended that blood draws are 
specifically conducted in a state of fasting so that serum triglycerides (TG) and LDL 
cholesterol (LDL-C) levels are more meaningful. Also, the fatty acid content of the 
coconut oil supplement is considerably greater when compared to that of the fish oil 
supplement. This may have influenced the difference in the change observed with the two 
supplements. Based on effective doses in previous research, it is recommended that a 
larger fish oil dose of 3000 to 5000 mg per day be used in future studies.  Finally, 
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conducting a study over a longer period of time may be necessary to see more significant 
results. 
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Screening 
(Visit 1) 
-Informed consent 
-Health history questionnaire 
-Food frequency questionnaire 
-Blood type check 
Baseline - Week 0 
(Visit 2) 
-First venous blood 
sample to assess 
baseline biomarkers                             
-Distribute supplements 
Week 8 
(Visit 3) 
-Post-intervention  
-Second venous blood sample 
-Pill count and calendar check 
-24 hour recall 
-Debriefing 
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Puritan’s Pride Organic Coconut Oil 1000 mg Supplement Facts 
Serving Size 2 Softgels 
 
Servings Per Container 60 
 
Amount Per Serving % Daily Value 
 
Calories 25 
 
 
Calories from Fat 25 
 
 
Total Fat 2.5 g 4%* 
 
Saturated Fat 2.5 g 12%* 
 
Protein <1 g * 
 
Organic Coconut Oil 2,000 mg (2 g) ** 
  (Cocos nucifera) (fruit) 
 
which typically contains: 
 
 
Lauric Acid 880 mg ** 
 
Myristic Acid 260 mg ** 
 
Caprylic Acid 106 mg ** 
 
Palmitic Acid 150 mg ** 
 
Capric Acid 90 mg ** 
 
Oleic Acid 100 mg ** 
 
Stearic Acid 20 mg ** 
 
Linoleic Acid 20 mg ** 
 
*Percent Daily Values are based on a 2,000 calorie diet. 
 
 
**Daily Value not established. 
 
 
EnergyFirst OmegaEnergy Fish Oil 1000 mg Supplement Facts 
Serving Size 1 Softgel 
 
Servings Per Container 60 
 
Amount Per Serving % Daily Value 
 
Calories 10 
 
 
Calories from Fat 10 
 
 
Total Fat 1 g 2%** 
 
Polyunsaturated Fat 0.5 g* 
 
Vitamin E 2 IU 7% 
 
Fish Oil 1000 mg* 
 
     EPA (Eicosapentaenoic Acid) 400 mg 
 
     DHA (Docosahexaenoic Acid) 200 mg 
**Percent Daily Values are based on a 2000 calorie diet. 
*Daily Value not established. 
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Calculations 
BMI = weight (kg)/height (m
2
) 
Friedewald Equation: LDL-C = TC - (HDL-C + TG/5) 
 
 
 
